Your browser doesn't support javascript.
loading
Epidemiological profile of COVID-19 in patients with prostate cancer undergoing androgen deprivation therapy at a Brazilian Cancer Center
Travalini, Isabela Granato; Vergamini, Lucas Bonachi; Silva, Ivan Leonardo Avelino Franca e; Caruso, Pedro; Orellana, Fernanda Monteiro; Curado, Maria Paula; Zequi, Stênio de Cássio.
Afiliação
  • Travalini, Isabela Granato; Universidade Nove de Julho. São Paulo. BR
  • Vergamini, Lucas Bonachi; A.C.Camargo Cancer Center. São Paulo. BR
  • Silva, Ivan Leonardo Avelino Franca e; A.C.Camargo Cancer Center. São Paulo. BR
  • Caruso, Pedro; A.C.Camargo Cancer Center. São Paulo. BR
  • Orellana, Fernanda Monteiro; Universidade Federal de São Paulo. São Paulo. BR
  • Curado, Maria Paula; A.C.Camargo Cancer Center. São Paulo. BR
  • Zequi, Stênio de Cássio; A.C.Camargo Cancer Center. São Paulo. BR
Einstein (São Paulo, Online) ; 21: eAO0273, 2023. tab, graf
Article em En | LILACS-Express | LILACS | ID: biblio-1520860
Biblioteca responsável: BR1.1
ABSTRACT
ABSTRACT Objective To describe the epidemiological aspects of COVID-19 in patients with prostate cancer who received androgen deprivation therapy and those who did not. Methods We retrospectively analyzed the medical records of patients with prostate cancer undergoing androgen deprivation therapy and those who did not undergo androgen deprivation therapy. These patients were treated at the A.C.Camargo Cancer Center between March 2020 and March 2021. Results Of the 78 patients with prostate cancer and positive RT-PCR test results, 50% were undergoing androgen deprivation therapy, and 49% were experiencing a non-metastatic biochemical relapse. Of these, 80.6% were symptomatic on the day of examination compared to 97.2% in the Control Group. A total of 82.1% of the patients receiving androgen deprivation therapy required hospitalization, with 30.8% admitted to the intensive care unit compared to 21.6% in the Control Group. There was no statistically significant difference in the use of a high-flow oxygen cannula, the need for orotracheal intubation and mechanical ventilation, the need for dialysis, multiple organ failure, or death. A significant difference was found between the groups in terms of the average length of stay in the intensive care unit. Conclusion Androgen deprivation therapy was not associated with protective factors or potential treatments in patients with prostate cancer and COVID-19. Although the number of patients analyzed was limited, and there may have been a selection bias, this is a unique study that cannot be expanded or replicated in similar (unvaccinated) populations.
Palavras-chave
Texto completo
Adicionar na Minha BVS
Imprimir
XML
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: LILACS País/Região como assunto: America do sul / Brasil Idioma: En Revista: Einstein (São Paulo, Online) Assunto da revista: Medicina Ano de publicação: 2023 Tipo de documento: Article País de afiliação: Brasil País de publicação: Brasil
Texto completo
Adicionar na Minha BVS
Imprimir
XML
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: LILACS País/Região como assunto: America do sul / Brasil Idioma: En Revista: Einstein (São Paulo, Online) Assunto da revista: Medicina Ano de publicação: 2023 Tipo de documento: Article País de afiliação: Brasil País de publicação: Brasil